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Abstract
Background Eczema herpeticum (EH) is a disseminated viral infection of eczematous skin disease with the herpes
simplex virus. Knowledge on clinical characteristics, risk factors and recurrent disease is limited. Our aim was to better
define clinical characteristics and risk factors for EH and especially for recurrent EH.
Methods A retrospective analysis of EH cases assessed the history, clinical signs, prior treatment and laboratory
results using a predefined questionnaire.
Results A total of 224 EH cases from eight European centres were included. Extrinsic AD was identified as risk factor
for EH, and only one patient suffered from intrinsic AD. Early onset of AD was identified as risk factor for recurrent EH.
Pretreatment with topical steroids, systemic steroids, topical calcineurin inhibitors or plain emollients reflected standard
therapy. Many patients showed AD lesions without EH, but skin without AD lesions was never affected by herpetic
lesions.
Conclusion Patients with clinically active, extrinsic AD are at risk of EH. Recurrent EH is associated with confounders
of severe atopic distortion and requires active AD lesions for clinical manifestation. Recurrent eczema herpeticum mainly
affects patients with early onset of AD.
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Introduction
Eczema herpeticum is an acute, severe skin condition found in
subjects with atopic dermatitis (AD). It presents with dissemi-
nated, monomorphic vesicles and can be accompanied by lym-
phadenopathy or fever.1 Before the invention of acyclovir, the
disease led to fatal outcomes with a mortality rate of up to 70%.2
If EH is suspected in a patient, acyclovir or valcyclovir should be
initiated immediately, since a delay can increase the length of
hospitalization.3,4
Whilst AD is the most common chronic inflammatory skin
disease, EH is a rare condition with an occurrence of 3%
amongst a subset of AD patients.5 This suggests that certain risk
factors influence the likelihood of developing EH. Multiple dis-
advantages of eczematous skin of AD subjects were associated
with the uncontrolled replication of HSV in affected lesions. The
disruption of cell junctions unmasks nectin-1, enabling the virus
to enter the cell.6,7 The antiviral immune response in AD is defi-
cient due to the lack of plasmacytoid dendritic cells, thus
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resulting in an insufficient IFN-c production.8 Defects in IFN-c
response are associated with a higher risk of viral skin infec-
tions.9 Furthermore, the AD-associated cathelicidin deficiency is
a predisposing factor for EH.10 Recent data indicated an elevated
type 2 response by virus-specific T cells may contribute to the
higher susceptibility to viral infections.11 The majority of EH
cases is caused by HSV-1 with F1 and F35 being the predomi-
nant genotypes according to a Japanese study.12
Very few studies addressing the susceptibility of AD patients
for EH have been performed on a larger number of EH
cases.13–15 A high rate of skin infections with other microbes, a
high total serum IgE and an early onset of AD were associated
with the occurrence of EH.14,15 Several case reports indicate that
multiple episodes of EH may occur in one patient.16–19
We performed a retrospective analysis of 224 cases of EH, to
identify novel clinical characteristics of EH, as well as risk factors
of recurrent EH.
Methods
Study design and clinical data
This study is a retrospective analysis of 224 cases of EH seen
over the course of 10 years by dermatological units at eight
European university hospitals. The diagnosis was made by a
dermatologist, and the data were then collected using a pre-
defined questionnaire, which included the date of first EH
symptoms, the date of EH diagnosis, concomitant diseases,
list of medication, history of atopy, family history of atopy,
date of diagnosis of AD, history of previous HSV infections,
history of previous EH, history of recent exposition to HSV
and meningeal or ocular involvement.
Topical and systemic therapies of patients were assessed for
up to 4 weeks before onset of EH to evaluate possible effects of
AD treatment on EH.
Extrinsic vs. intrinsic AD subtypes
To differentiate between extrinsic and intrinsic AD, the patient’s
history of atopy and the results of skin prick tests, total serum
IgE levels, SX-1-CAP-FEIA and FX-5-CAP-FEIA were checked.
AD was categorized according to W€uthrich as extrinsic if the
patient presented one or several of the following features: ele-
vated total serum IgE levels (≥100 kU/L), positive results in
standard skin prick tests, positive SX-1- or FX-5-CAP-FEIA, a
history of allergic rhinoconjunctivitis (RCA) or allergic bron-
chial asthma.20
Scoring of AD severity
Severity of AD was assessed by SCOring of Atopic Dermatitis
(SCORAD) and Rajka–Langeland severity grading. The Rajka–
Langeland score allows to distinguish between mild, moderate
and severe AD by grading extent, course and intensity of the dis-
ease.21 The highest possible score is 9. The SCORAD permits to
evaluate extent, severity and subjective symptoms.22 To assess
the intensity, erythema, oedema/papulation, oozing/crusts, exco-
riations, lichenification and dryness are evaluated as separate
subcategories. The highest possible score in this scoring system
is 103. The areas affected by AD, as well as the areas affected by
EH, were estimated by hatching of predefined human body
drawings.
Determination of primary vs. secondary HSV infection
Primary or secondary HSV infections were determined accord-
ing to a predefined algorithm utilizing the patient’s history and
serum levels of anti-HSV-IgM and -IgG antibodies, which were
available in 69 cases.
Statistical analysis
Mean values, minimum and maximum values, standard devia-
tion and P-values were calculated using SPSS statistics software
(IBM SPSS Statistics).
Results
Demographics of study population
A total of 224 cases of EH were included in the study, which had
occurred in 214 patients. Gender distribution was almost equal
with 122 male and 102 female patients. Patient’s mean age at
onset of EH was 27.3  11.9 years. The mean age of onset of
the underlying AD was 9.5  10.1 years (n = 104). Patients
with recurrent EH were slightly but insignificantly older (median
value 26 years) than those experiencing their first episode of EH
(median value 24 years). There was no significant age difference
between patients with primary and patients with secondary HSV
infection (19.83  12.1 years vs. 26.57  9.75 years).
Long diagnostic period
It took on average 4.2  3.4 days until patients were diagnosed
with EH after realizing their first symptoms (min 0 days and
max 21 days). Recurrent EH was diagnosed earlier
(4.0  2.69 days) compared with first episodes of EH
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Figure 1 A total of 133 patients suffered from a single episode of
EH, 31 patients sustained the disease twice, and 17 patients
endured more than two episodes. The recurrence rate was 26.5%.
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(4.4  3.74 days), but the difference was not significant
(P = 0.595).
Primary and secondary HSV infections may cause EH
Out of the 224 cases, 19 were clearly identified as primary HSV
infection. In 112 cases, EH was caused by a secondary HSV
infection. Naturally, recurrent episodes of EH were assessed as
secondary HSV infection. In 93 cases, conclusive data were
missing.
26.5% EH recurrence rate
A total of 133 patients (n = 181) suffered from their first episode
of EH, 31 patients endured the disease twice, and 17 patients suf-
fered from more than two episodes (Fig. 1). One patient
endured seven episodes, which was the highest number of EH
episodes in this study. The numbers add up to a recurrence rate
of 26.5% (Fig. 1).
Recurrent EH is associated with early onset of AD
High disease severity of the underlying AD and an early age
of AD onset have been identified as predisposing factors for
EH in previous studies.14,15 To check whether those factors
can be associated with recurrent EH, our study compared
disease severity assessed by Rajka–Langeland scores, SCORAD
index, affected body surface area and the age of AD onset in
patients with one episode of EH to patients with multiple
episodes of EH. EH patients in the study presented with a
mean score of 6.34  1.77 in Rajka–Langeland score and
44.21  18.17 in SCORAD (n = 89). Patients with a single
episode of EH presented with a mean SCORAD of 42.28 and
a mean affected body surface area of 34.4%. Patients with
multiple episodes of EH showed mean SCORAD levels of
46.12 and 44.6% affected body surface area. Both parameters
were slightly, but insignificantly higher in patients with recur-
rent AD.
The comparison of age of onset showed that patients with
recurrent EH were significantly younger at onset of the underly-
ing AD (5.43  12.9 years of age) opposed to patients with just
a single EH episode (11.1  6.5 years of age) (P = 0.016,
n = 104) (Fig 2 and Fig. 3).
Allergological characteristics of EH patients
In our patient cohort, 66.1% reported a history of RCA, and
37.5% reported a history of asthma. The average serum total IgE
level was 976.64 kU/L, with a minimum of 17 kU/L and a maxi-
mum of 37 940 kU/L (n = 102). There was no significant differ-
ence in serum IgE levels of patients with one episode of EH
opposed to patients with multiple episodes (Fig. 4).
Extrinsic AD is a risk factor for EH
According to the criteria named above, 184 cases of EH occurred
in patients with extrinsic AD. Only one patient in the study pre-
sented with an intrinsic form of AD. The difference was statisti-
cally highly significant (P < 0.001, n = 185). Conclusive data
regarding the extrinsic/intrinsic status were missing in 39 cases.
Prior treatment has no influence on EH development
Both topical treatment and systemic treatment used up to
4 weeks prior to onset of EH were analysed. A total of 76
patients had used at least once topical steroids, 15 at least once
tacrolimus ointment and 5 pimecrolimus cream at least once in
the last 4 weeks before onset of EH. However, 23 patient had
exclusively used emollients and 32 patients had not received any
topical treatment at all (n = 151) (Fig. 5a). This adds up to 55
patients, who did not receive any topical anti-inflammatory
treatment prior to the EH.
A total of 118 patients did not receive any systemic treatment
prior to their EH, 10 patients received systemic corticosteroids, 2
received cyclosporine A, and 1 patient received both corticos-
teroids and cyclosporine A in the last 4 weeks prior to onset of
their EH (n = 131) (Fig. 5b).
Herpetic lesions are restricted to body areas affected by
visible AD lesions
The distribution of EH lesions and AD lesions was assessed by
two different methods: shading of body drawings and explicit
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Figure 2 Patients with recurrent EH were significantly younger at
onset of AD.
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questions for the presence of AD areas without herpetic lesions,
as well as herpetic lesions outside of the areas of AD. EH lesions
were only found in areas previously affected by the underlying
AD. EH lesions did not appear in non-lesional skin regions
(n = 126). The information was not available to us in all of the
224 cases.
Discussion
This multicenter study was performed to reveal further informa-
tion about the clinical characteristics and risk factors for EH in
general and especially of recurrent EH. Extrinsic AD displayed
the main risk factor for EH. Early onset of AD was identified as
risk factor for recurrent EH. Pretreatment with topical steroids,
systemic steroids, topical calcineurin inhibitors or emollients
reflected standard therapy.23 Skin without AD lesions was never
affected by herpetic lesions. Four larger retrospective studies on
EH have been published so far, and our study represents the lar-
gest number of cases and is the only study that highlights risk
factors for EH recurrence.13–15,24
The recurrence rate of EH was 26.5% in our study. The rate
seems to vary drastically between studies. Previous studies noted
rates of recurrence between 12% and 50%.13–15,24
A Canadian study including 79 patients indicated that hospi-
talized patients have an increased risk of EH recurrence.24 Since
EH is a rare disease, there are no distinct and validated criteria
as to when a patient should be hospitalized. Therefore, hospital-
ization is usually a discretionary decision of the treating physi-
cian. It is common sense that hospital admissions are more
likely to occur in severe cases. Thus, defining further risk factors
besides hospitalization seems crucial.
An early onset of the underlying AD is associated with more
severe disease and a known risk factor for EH.15 In our study,
patients with recurrent EH were significantly younger at AD
onset than patients with just a single episode of EH. This is a
novel finding, as it has never been assessed in larger studies. Our
results implicate that an early age of AD onset not only predis-
poses to EH manifestation, but also to EH recurrences.
A remarkable finding was the significantly higher number
(n = 189) of patients with extrinsic AD opposed to only one
patient with intrinsic AD. This suggests a correlation between
the atopic distortion of the patient and the disposition to EH
occurrence. The rate of patients with intrinsic AD is usually
about 10–40% according to larger studies.20,25–27 A previous
study showed that patients with extrinsic AD tend to have a
more severe, refractory type of AD opposed to patients without
signs of atopy.28 It has been reported that AD patients with a
positive history for food allergies or asthma are more likely to
develop EH, which further supports this hypothesis.14
The mean total IgE level in our patients was 976.64 U/mL,
the majority ranging between 1000 and 9999 U/mL (Fig. 4).
High IgE levels have been associated with EH previously.15,29
However, our study did not see a correlation between high
IgE levels and EH recurrence. A greater TH2 polarity may
explain the higher IgE levels in extrinsic AD. In addition,
extrinsic and intrinsic AD patients show different cytokine
activation patterns.30 Cytokines secreted by TH2 cells can
induce apoptosis of plasmacytoid dendritic cells.30 A lack of
these cells leads to a deficient IFN-c production and results
in a higher susceptibility to viral infections.8 This idea is
endorsed by a study, which demonstrated high IgE levels, but
low IFN-c levels in patients with EH.29 The importance of
TH2 cells in EH development is also reflected in our finding,
that an early onset of AD is a risk factor for EH. Patients
with early onset of AD present very low TH1 cell activation,
but excessive production of TH2 cells.30 Recent data support
the theory that the TH2 response largely contributes to the
pathology of EH.11 An elevated type 2 cell response to HSV
was found in AD patients.
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Figure 4 Serum IgE levels of patients with singular and multiple
EH episodes, differences were insignificant.
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With a mean SCORAD of 44.2 and a mean Rajka–Langeland
score of 6.34, our study supports the hypothesis that patients
with moderate-to-severe AD are more likely to develop EH.14
However, there was no significant difference in disease severity
between patients with one episode of EH and patients with
recurrent EH. To further evaluate the role of disease severity in
recurrence of EH, long-term follow-ups of patients with EH
would be needed. Currently, we cannot clearly state whether
patients were spared from recurrence due to improvement of
skin lesions or for other reasons.
Besides the missing data on long-term follow-ups of the
patients, the data set was not complete for all readouts. This was
due to the retrospective design of the study. Because of the large
number of cases, we were still able to detect valuable informa-
tion on EH and its risk factors.
Some authors discussed an association of EH with the use of
topical steroids or topical calcineurin inhibitors.13,18 Other
authors assumed that the use of corticosteroids does not seem to
impact EH manifestation.15,31 Our results support the assump-
tion that there is no correlation between EH occurrence and the
previously used AD treatment, as most patients had not received
any systemic treatment prior to the event, and 55 patients had
not received a topical anti-inflammatory treatment. Untreated
AD lesions may actually be more prone to EH, considering that
severe AD has been identified as risk factor for EH.14 Topical
steroids or calcineurin inhibitors may even be used to treat the
underlying AD in patients with EH. A study showed that the use
of such treatments is not associated with a poorer outcome of
EH.32 To the contrary, the discontinuation of topical corticos-
teroids may actually contribute to the outbreak of EH. This was
associated with elevation of regulatory T cells and proinflamma-
tory monocytes after the withdrawal of corticosteroids.33
The number of male patients was slightly higher in our study
than that of female patients. Male predominance has been
described for EH in a study including 50 Korean children and
was therefore defined as risk factor for EH.34 Other large-scale
studies showed an insignificant female predominance.14,15,35
Taken together, gender is most probably not a risk factor for
EH.
It took an average of 4 days until the patients in our study
were diagnosed with EH. This delay of diagnosis and treatment
has not been addressed in any larger study before. The time
frame seems unacceptably long, considering the high mortality
of untreated disseminated HSV infections.2 Delayed initiation of
acyclovir is associated with an increased length of stay of hospi-
talized EH patients, and just recently, a lethal case of EH has
been reported.3,36 Therefore, immediate diagnosis and treatment
initiation are crucial.
Our patients with recurrent EH were diagnosed a little sooner,
but not significantly. It could be expected that patients having
ever experienced an episode of EH would seek medical help and
treatment sooner because they know what to expect in the next
days, but this was not the case.
The morphology of the vesicles in EH has been described
multiple times, but information about the distribution pattern
was lacking.14,15,37 This study was able to demonstrate that EH
lesions will only affect lesional AD skin. Areas of the skin that do
not show signs of eczema will be spared from the characteristic
vesicular eruption. This was true in all 126 cases of EH in this
study, where distribution was documented. Conclusively, the
spread of EH lesions is limited by the distribution pattern of the
underlying AD. This information can help to differentiate EH
from other skin conditions and will hopefully lead to a faster
diagnosis of affected patients.
Clinical implications
Eczema herpeticum occurs almost exclusively in extrinsic AD
patients. An early onset of AD is associated with the develop-
ment of EH, and in addition a predisposing factor of recurrent
EH. The spread of EH lesions is limited by the distribution of
the underlying AD.
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